APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Adalimumab Injection

Compare research editions
View pricing & licenses

Selected research

Industry Research

Adalimumab Injection Industry Research Report 2026

Report ID 173960450522 December 2025133 pages

Choose your research edition.

Industry ResearchAdalimumab Injection Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal Adalimumab Injection Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Adalimumab Injection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Adalimumab Injection Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Adalimumab Injection Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Adalimumab Injection market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Adalimumab Injection is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Adalimumab Injection is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Adalimumab Injection is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Adalimumab Injection include Jiangsu Chia Tai-Tianqing Pharmaceutical, Innovent Biologics, Sandoz, Mylan, Hisun Biopharmaceutical, Shanghai Henlius Biotech, Fresenius Kabi, Bio-Thera Solutions, Ltd. and Amgen, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Adalimumab Injection market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Adalimumab Injection Market by Company

Jiangsu Chia Tai-Tianqing Pharmaceutical

Innovent Biologics

Sandoz

Mylan

Hisun Biopharmaceutical

Shanghai Henlius Biotech

Fresenius Kabi

Bio-Thera Solutions, Ltd.

Amgen

AbbVie

Zydus Group

Celltrion

Cadila Pharmaceuticals

Boehringer Ingelheim

Biogen

Adalimumab Injection Segment by Type

40mg/0.8ml

20mg/0.4ml

Adalimumab Injection Segment by Application

Hospitals

Clinics

Others

Adalimumab Injection Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Adalimumab Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Adalimumab Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Adalimumab Injection.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Adalimumab Injection manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Adalimumab Injection by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Adalimumab Injection in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Adalimumab Injection Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Adalimumab Injection Sales (k units) of Manufacturers (2021-2026) Table 7. Global Adalimumab Injection Sales Market Share by Manufacturers (2021-2026) Table 8. Global Adalimumab Injection Revenue of Manufacturers (2021-2026) Table 9. Global Adalimumab Injection Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Adalimumab Injection Average Price (US$/unit) of Manufacturers (2021-2026) Table 11. Global Adalimumab Injection Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Adalimumab Injection, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Adalimumab Injection, Product Type & Application Table 14. Global Adalimumab Injection Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Adalimumab Injection by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Jiangsu Chia Tai-Tianqing Pharmaceutical Company Information Table 19. Jiangsu Chia Tai-Tianqing Pharmaceutical Business Overview Table 20. Jiangsu Chia Tai-Tianqing Pharmaceutical Adalimumab Injection Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 21. Jiangsu Chia Tai-Tianqing Pharmaceutical Adalimumab Injection Product Portfolio Table 22. Jiangsu Chia Tai-Tianqing Pharmaceutical Recent Developments Table 23. Innovent Biologics Company Information Table 24. Innovent Biologics Business Overview Table 25. Innovent Biologics Adalimumab Injection Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 26. Innovent Biologics Adalimumab Injection Product Portfolio Table 27. Innovent Biologics Recent Developments Table 28. Sandoz Company Information Table 29. Sandoz Business Overview Table 30. Sandoz Adalimumab Injection Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 31. Sandoz Adalimumab Injection Product Portfolio Table 32. Sandoz Recent Developments Table 33. Mylan Company Information Table 34. Mylan Business Overview Table 35. Mylan Adalimumab Injection Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 36. Mylan Adalimumab Injection Product Portfolio Table 37. Mylan Recent Developments Table 38. Hisun Biopharmaceutical Company Information Table 39. Hisun Biopharmaceutical Business Overview Table 40. Hisun Biopharmaceutical Adalimumab Injection Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 41. Hisun Biopharmaceutical Adalimumab Injection Product Portfolio Table 42. Hisun Biopharmaceutical Recent Developments Table 43. Shanghai Henlius Biotech Company Information Table 44. Shanghai Henlius Biotech Business Overview Table 45. Shanghai Henlius Biotech Adalimumab Injection Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 46. Shanghai Henlius Biotech Adalimumab Injection Product Portfolio Table 47. Shanghai Henlius Biotech Recent Developments Table 48. Fresenius Kabi Company Information Table 49. Fresenius Kabi Business Overview Table 50. Fresenius Kabi Adalimumab Injection Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 51. Fresenius Kabi Adalimumab Injection Product Portfolio Table 52. Fresenius Kabi Recent Developments Table 53. Bio-Thera Solutions, Ltd. Company Information Table 54. Bio-Thera Solutions, Ltd. Business Overview Table 55. Bio-Thera Solutions, Ltd. Adalimumab Injection Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 56. Bio-Thera Solutions, Ltd. Adalimumab Injection Product Portfolio Table 57. Bio-Thera Solutions, Ltd. Recent Developments Table 58. Amgen Company Information Table 59. Amgen Business Overview Table 60. Amgen Adalimumab Injection Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 61. Amgen Adalimumab Injection Product Portfolio Table 62. Amgen Recent Developments Table 63. AbbVie Company Information Table 64. AbbVie Business Overview Table 65. AbbVie Adalimumab Injection Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. AbbVie Adalimumab Injection Product Portfolio Table 67. AbbVie Recent Developments Table 68. Zydus Group Company Information Table 69. Zydus Group Business Overview Table 70. Zydus Group Adalimumab Injection Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Zydus Group Adalimumab Injection Product Portfolio Table 72. Zydus Group Recent Developments Table 73. Celltrion Company Information Table 74. Celltrion Business Overview Table 75. Celltrion Adalimumab Injection Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Celltrion Adalimumab Injection Product Portfolio Table 77. Celltrion Recent Developments Table 78. Cadila Pharmaceuticals Company Information Table 79. Cadila Pharmaceuticals Business Overview Table 80. Cadila Pharmaceuticals Adalimumab Injection Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Cadila Pharmaceuticals Adalimumab Injection Product Portfolio Table 82. Cadila Pharmaceuticals Recent Developments Table 83. Boehringer Ingelheim Company Information Table 84. Boehringer Ingelheim Business Overview Table 85. Boehringer Ingelheim Adalimumab Injection Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Boehringer Ingelheim Adalimumab Injection Product Portfolio Table 87. Boehringer Ingelheim Recent Developments Table 88. Biogen Company Information Table 89. Biogen Business Overview Table 90. Biogen Adalimumab Injection Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Biogen Adalimumab Injection Product Portfolio Table 92. Biogen Recent Developments Table 93. Global Adalimumab Injection Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 94. Global Adalimumab Injection Sales by Region (2021-2026) & (k units) Table 95. Global Adalimumab Injection Sales Market Share by Region (2021-2026) Table 96. Global Adalimumab Injection Sales by Region (2027-2032) & (k units) Table 97. Global Adalimumab Injection Sales Market Share by Region (2027-2032) Table 98. Global Adalimumab Injection Revenue by Region (2021-2026) & (US$ Million) Table 99. Global Adalimumab Injection Revenue Market Share by Region (2021-2026) Table 100. Global Adalimumab Injection Revenue by Region (2027-2032) & (US$ Million) Table 101. Global Adalimumab Injection Revenue Market Share by Region (2027-2032) Table 102. North America Adalimumab Injection Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 103. North America Adalimumab Injection Sales by Country (2021-2026) & (k units) Table 104. North America Adalimumab Injection Sales by Country (2027-2032) & (k units) Table 105. North America Adalimumab Injection Revenue by Country (2021-2026) & (US$ Million) Table 106. North America Adalimumab Injection Revenue by Country (2027-2032) & (US$ Million) Table 107. Europe Adalimumab Injection Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. Europe Adalimumab Injection Sales by Country (2021-2026) & (k units) Table 109. Europe Adalimumab Injection Sales by Country (2027-2032) & (k units) Table 110. Europe Adalimumab Injection Revenue by Country (2021-2026) & (US$ Million) Table 111. Europe Adalimumab Injection Revenue by Country (2027-2032) & (US$ Million) Table 112. Asia Pacific Adalimumab Injection Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. Asia Pacific Adalimumab Injection Sales by Country (2021-2026) & (k units) Table 114. Asia Pacific Adalimumab Injection Sales by Country (2027-2032) & (k units) Table 115. Asia Pacific Adalimumab Injection Revenue by Country (2021-2026) & (US$ Million) Table 116. Asia Pacific Adalimumab Injection Revenue by Country (2027-2032) & (US$ Million) Table 117. South America Adalimumab Injection Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. South America Adalimumab Injection Sales by Country (2021-2026) & (k units) Table 119. South America Adalimumab Injection Sales by Country (2027-2032) & (k units) Table 120. South America Adalimumab Injection Revenue by Country (2021-2026) & (US$ Million) Table 121. South America Adalimumab Injection Revenue by Country (2027-2032) & (US$ Million) Table 122. Middle East and Africa Adalimumab Injection Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. Middle East and Africa Adalimumab Injection Sales by Country (2021-2026) & (k units) Table 124. Middle East and Africa Adalimumab Injection Sales by Country (2027-2032) & (k units) Table 125. Middle East and Africa Adalimumab Injection Revenue by Country (2021-2026) & (US$ Million) Table 126. Middle East and Africa Adalimumab Injection Revenue by Country (2027-2032) & (US$ Million) Table 127. Global Adalimumab Injection Sales by Type (2021-2026) & (k units) Table 128. Global Adalimumab Injection Sales by Type (2027-2032) & (k units) Table 129. Global Adalimumab Injection Sales Market Share by Type (2021-2026) Table 130. Global Adalimumab Injection Sales Market Share by Type (2027-2032) Table 131. Global Adalimumab Injection Revenue by Type (2021-2026) & (US$ Million) Table 132. Global Adalimumab Injection Revenue by Type (2027-2032) & (US$ Million) Table 133. Global Adalimumab Injection Revenue Market Share by Type (2021-2026) Table 134. Global Adalimumab Injection Revenue Market Share by Type (2027-2032) Table 135. Global Adalimumab Injection Price by Type (2021-2026) & (US$/unit) Table 136. Global Adalimumab Injection Price by Type (2027-2032) & (US$/unit) Table 137. Global Adalimumab Injection Sales by Application (2021-2026) & (k units) Table 138. Global Adalimumab Injection Sales by Application (2027-2032) & (k units) Table 139. Global Adalimumab Injection Sales Market Share by Application (2021-2026) Table 140. Global Adalimumab Injection Sales Market Share by Application (2027-2032) Table 141. Global Adalimumab Injection Revenue by Application (2021-2026) & (US$ Million) Table 142. Global Adalimumab Injection Revenue by Application (2027-2032) & (US$ Million) Table 143. Global Adalimumab Injection Revenue Market Share by Application (2021-2026) Table 144. Global Adalimumab Injection Revenue Market Share by Application (2027-2032) Table 145. Global Adalimumab Injection Price by Application (2021-2026) & (US$/unit) Table 146. Global Adalimumab Injection Price by Application (2027-2032) & (US$/unit) Table 147. Key Raw Materials Table 148. Raw Materials Key Suppliers Table 149. Adalimumab Injection Distributors List Table 150. Adalimumab Injection Customers List Table 151. Adalimumab Injection Industry Trends Table 152. Adalimumab Injection Industry Drivers Table 153. Adalimumab Injection Industry Restraints Table 154. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Adalimumab Injection Product Image Figure 5. Global Adalimumab Injection Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Adalimumab Injection Market Size (2021-2032) & (US$ Million) Figure 7. Global Adalimumab Injection Sales (2021-2032) & (k units) Figure 8. Global Adalimumab Injection Average Price (US$/unit) & (2021-2032) Figure 9. 40mg/0.8ml Product Image Figure 10. 20mg/0.4ml Product Image Figure 11. Hospitals Product Image Figure 12. Clinics Product Image Figure 13. Others Product Image Figure 14. Global Adalimumab Injection Revenue Share by Manufacturers in 2025 Figure 15. Global Manufacturers of Adalimumab Injection, Manufacturing Sites & Headquarters Figure 16. Global Top 5 and 10 Adalimumab Injection Players Market Share by Revenue in 2025 Figure 17. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Adalimumab Injection Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 19. Global Adalimumab Injection Sales by Region in 2025 Figure 20. Global Adalimumab Injection Revenue by Region in 2025 Figure 21. North America Adalimumab Injection Market Size by Country in 2025 Figure 22. North America Adalimumab Injection Sales Market Share by Country (2021-2032) Figure 23. North America Adalimumab Injection Revenue Market Share by Country (2021-2032) Figure 24. United States Adalimumab Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 25. Canada Adalimumab Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Mexico Adalimumab Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Europe Adalimumab Injection Market Size by Country in 2025 Figure 28. Europe Adalimumab Injection Sales Market Share by Country (2021-2032) Figure 29. Europe Adalimumab Injection Revenue Market Share by Country (2021-2032) Figure 30. Germany Adalimumab Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. France Adalimumab Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. U.K. Adalimumab Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Italy Adalimumab Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Russia Adalimumab Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Spain Adalimumab Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Netherlands Adalimumab Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Switzerland Adalimumab Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Sweden Adalimumab Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Poland Adalimumab Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Asia Pacific Adalimumab Injection Market Size by Country in 2025 Figure 41. Asia Pacific Adalimumab Injection Sales Market Share by Country (2021-2032) Figure 42. Asia Pacific Adalimumab Injection Revenue Market Share by Country (2021-2032) Figure 43. China Adalimumab Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Japan Adalimumab Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. South Korea Adalimumab Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. India Adalimumab Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Australia Adalimumab Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Taiwan Adalimumab Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Southeast Asia Adalimumab Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Southeast Asia Adalimumab Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. South America Adalimumab Injection Market Size by Country in 2025 Figure 52. South America Adalimumab Injection Sales Market Share by Country (2021-2032) Figure 53. South America Adalimumab Injection Revenue Market Share by Country (2021-2032) Figure 54. Brazil Adalimumab Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Argentina Adalimumab Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Chile Adalimumab Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Middle East and Africa Adalimumab Injection Market Size by Country in 2025 Figure 58. Middle East and Africa Adalimumab Injection Sales Market Share by Country (2021-2032) Figure 59. Middle East and Africa Adalimumab Injection Revenue Market Share by Country (2021-2032) Figure 60. Egypt Adalimumab Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. South Africa Adalimumab Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Israel Adalimumab Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. Türkiye Adalimumab Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. GCC Countries Adalimumab Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Global Adalimumab Injection Sales Market Share by Type (2021-2032) Figure 66. Global Adalimumab Injection Revenue Market Share by Type (2021-2032) Figure 67. Global Adalimumab Injection Price (US$/unit) by Type (2021-2032) Figure 68. Global Adalimumab Injection Sales Market Share by Application (2021-2032) Figure 69. Global Adalimumab Injection Revenue Market Share by Application (2021-2032) Figure 70. Global Adalimumab Injection Price (US$/unit) by Application (2021-2032) Figure 71. Adalimumab Injection Value Chain Figure 72. Adalimumab Injection Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Adalimumab Injection Industry Opportunities and Challenges

Scope & coverage.

Types
  • 40mg/0.8ml
  • 20mg/0.4ml
Applications
  • Hospitals
  • Clinics
  • Others
Companies covered
  • Jiangsu Chia Tai-Tianqing Pharmaceutical
  • Innovent Biologics
  • Sandoz
  • Mylan
  • Hisun Biopharmaceutical
  • Shanghai Henlius Biotech
  • Fresenius Kabi
  • Bio-Thera Solutions, Ltd.
  • Amgen
  • AbbVie
  • Zydus Group
  • Celltrion
  • Cadila Pharmaceuticals
  • Boehringer Ingelheim
  • Biogen

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Adalimumab Injection Market Size (2021-2032)
  4. 2.2.2 Global Adalimumab Injection Sales (2021-2032)
  5. 2.2.3 Global Adalimumab Injection Market Average Price (2021-2032)
  6. 2.3 Adalimumab Injection by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 40mg/0.8ml
  9. 2.3.3 20mg/0.4ml
  10. 2.4 Adalimumab Injection by Application
  11. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  12. 2.4.2 Hospitals
  13. 2.4.3 Clinics
  14. 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Adalimumab Injection Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Adalimumab Injection Sales (k units) of Manufacturers (2021-2026)
  3. 3.3 Global Adalimumab Injection Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Adalimumab Injection Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Adalimumab Injection Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Adalimumab Injection, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Adalimumab Injection, Product Type & Application
  8. 3.8 Global Manufacturers of Adalimumab Injection, Established Date
  9. 3.9 Global Adalimumab Injection Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Jiangsu Chia Tai-Tianqing Pharmaceutical
  2. 4.1.1 Jiangsu Chia Tai-Tianqing Pharmaceutical Company Information
  3. 4.1.2 Jiangsu Chia Tai-Tianqing Pharmaceutical Business Overview
  4. 4.1.3 Jiangsu Chia Tai-Tianqing Pharmaceutical Adalimumab Injection Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Jiangsu Chia Tai-Tianqing Pharmaceutical Adalimumab Injection Product Portfolio
  6. 4.1.5 Jiangsu Chia Tai-Tianqing Pharmaceutical Recent Developments
  7. 4.2 Innovent Biologics
  8. 4.2.1 Innovent Biologics Company Information
  9. 4.2.2 Innovent Biologics Business Overview
  10. 4.2.3 Innovent Biologics Adalimumab Injection Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Innovent Biologics Adalimumab Injection Product Portfolio
  12. 4.2.5 Innovent Biologics Recent Developments
  13. 4.3 Sandoz
  14. 4.3.1 Sandoz Company Information
  15. 4.3.2 Sandoz Business Overview
  16. 4.3.3 Sandoz Adalimumab Injection Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Sandoz Adalimumab Injection Product Portfolio
  18. 4.3.5 Sandoz Recent Developments
  19. 4.4 Mylan
  20. 4.4.1 Mylan Company Information
  21. 4.4.2 Mylan Business Overview
  22. 4.4.3 Mylan Adalimumab Injection Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Mylan Adalimumab Injection Product Portfolio
  24. 4.4.5 Mylan Recent Developments
  25. 4.5 Hisun Biopharmaceutical
  26. 4.5.1 Hisun Biopharmaceutical Company Information
  27. 4.5.2 Hisun Biopharmaceutical Business Overview
  28. 4.5.3 Hisun Biopharmaceutical Adalimumab Injection Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Hisun Biopharmaceutical Adalimumab Injection Product Portfolio
  30. 4.5.5 Hisun Biopharmaceutical Recent Developments
  31. 4.6 Shanghai Henlius Biotech
  32. 4.6.1 Shanghai Henlius Biotech Company Information
  33. 4.6.2 Shanghai Henlius Biotech Business Overview
  34. 4.6.3 Shanghai Henlius Biotech Adalimumab Injection Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Shanghai Henlius Biotech Adalimumab Injection Product Portfolio
  36. 4.6.5 Shanghai Henlius Biotech Recent Developments
  37. 4.7 Fresenius Kabi
  38. 4.7.1 Fresenius Kabi Company Information
  39. 4.7.2 Fresenius Kabi Business Overview
  40. 4.7.3 Fresenius Kabi Adalimumab Injection Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Fresenius Kabi Adalimumab Injection Product Portfolio
  42. 4.7.5 Fresenius Kabi Recent Developments
  43. 4.8 Bio-Thera Solutions, Ltd.
  44. 4.8.1 Bio-Thera Solutions, Ltd. Company Information
  45. 4.8.2 Bio-Thera Solutions, Ltd. Business Overview
  46. 4.8.3 Bio-Thera Solutions, Ltd. Adalimumab Injection Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Bio-Thera Solutions, Ltd. Adalimumab Injection Product Portfolio
  48. 4.8.5 Bio-Thera Solutions, Ltd. Recent Developments
  49. 4.9 Amgen
  50. 4.9.1 Amgen Company Information
  51. 4.9.2 Amgen Business Overview
  52. 4.9.3 Amgen Adalimumab Injection Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Amgen Adalimumab Injection Product Portfolio
  54. 4.9.5 Amgen Recent Developments
  55. 4.10 AbbVie
  56. 4.10.1 AbbVie Company Information
  57. 4.10.2 AbbVie Business Overview
  58. 4.10.3 AbbVie Adalimumab Injection Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 AbbVie Adalimumab Injection Product Portfolio
  60. 4.10.5 AbbVie Recent Developments
  61. 4.11 Zydus Group
  62. 4.11.1 Zydus Group Company Information
  63. 4.11.2 Zydus Group Business Overview
  64. 4.11.3 Zydus Group Adalimumab Injection Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Zydus Group Adalimumab Injection Product Portfolio
  66. 4.11.5 Zydus Group Recent Developments
  67. 4.12 Celltrion
  68. 4.12.1 Celltrion Company Information
  69. 4.12.2 Celltrion Business Overview
  70. 4.12.3 Celltrion Adalimumab Injection Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Celltrion Adalimumab Injection Product Portfolio
  72. 4.12.5 Celltrion Recent Developments
  73. 4.13 Cadila Pharmaceuticals
  74. 4.13.1 Cadila Pharmaceuticals Company Information
  75. 4.13.2 Cadila Pharmaceuticals Business Overview
  76. 4.13.3 Cadila Pharmaceuticals Adalimumab Injection Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Cadila Pharmaceuticals Adalimumab Injection Product Portfolio
  78. 4.13.5 Cadila Pharmaceuticals Recent Developments
  79. 4.14 Boehringer Ingelheim
  80. 4.14.1 Boehringer Ingelheim Company Information
  81. 4.14.2 Boehringer Ingelheim Business Overview
  82. 4.14.3 Boehringer Ingelheim Adalimumab Injection Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Boehringer Ingelheim Adalimumab Injection Product Portfolio
  84. 4.14.5 Boehringer Ingelheim Recent Developments
  85. 4.15 Biogen
  86. 4.15.1 Biogen Company Information
  87. 4.15.2 Biogen Business Overview
  88. 4.15.3 Biogen Adalimumab Injection Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Biogen Adalimumab Injection Product Portfolio
  90. 4.15.5 Biogen Recent Developments
5 Global Adalimumab Injection Market Scenario by Region
  1. 5.1 Global Adalimumab Injection Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Adalimumab Injection Sales by Region: 2021-2032
  3. 5.2.1 Global Adalimumab Injection Sales by Region: 2021-2026
  4. 5.2.2 Global Adalimumab Injection Sales by Region: 2027-2032
  5. 5.3 Global Adalimumab Injection Revenue by Region: 2021-2032
  6. 5.3.1 Global Adalimumab Injection Revenue by Region: 2021-2026
  7. 5.3.2 Global Adalimumab Injection Revenue by Region: 2027-2032
  8. 5.4 North America Adalimumab Injection Market Facts & Figures by Country
  9. 5.4.1 North America Adalimumab Injection Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Adalimumab Injection Sales by Country (2021-2032)
  11. 5.4.3 North America Adalimumab Injection Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Adalimumab Injection Market Facts & Figures by Country
  16. 5.5.1 Europe Adalimumab Injection Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Adalimumab Injection Sales by Country (2021-2032)
  18. 5.5.3 Europe Adalimumab Injection Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Adalimumab Injection Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Adalimumab Injection Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Adalimumab Injection Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Adalimumab Injection Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Adalimumab Injection Market Facts & Figures by Country
  41. 5.7.1 South America Adalimumab Injection Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Adalimumab Injection Sales by Country (2021-2032)
  43. 5.7.3 South America Adalimumab Injection Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Adalimumab Injection Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Adalimumab Injection Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Adalimumab Injection Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Adalimumab Injection Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Adalimumab Injection Sales by Type (2021-2032)
  2. 6.1.1 Global Adalimumab Injection Sales by Type (2021-2032) & (k units)
  3. 6.1.2 Global Adalimumab Injection Sales Market Share by Type (2021-2032)
  4. 6.2 Global Adalimumab Injection Revenue by Type (2021-2032)
  5. 6.2.1 Global Adalimumab Injection Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Adalimumab Injection Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Adalimumab Injection Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Adalimumab Injection Sales by Application (2021-2032)
  2. 7.1.1 Global Adalimumab Injection Sales by Application (2021-2032) & (k units)
  3. 7.1.2 Global Adalimumab Injection Sales Market Share by Application (2021-2032)
  4. 7.2 Global Adalimumab Injection Revenue by Application (2021-2032)
  5. 7.2.1 Global Adalimumab Injection Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Adalimumab Injection Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Adalimumab Injection Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Adalimumab Injection Value Chain Analysis
  2. 8.1.1 Adalimumab Injection Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Adalimumab Injection Production Mode & Process
  5. 8.2 Adalimumab Injection Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Adalimumab Injection Distributors
  8. 8.2.3 Adalimumab Injection Customers
9 Global Adalimumab Injection Analyzing Market Dynamics
  1. 9.1 Adalimumab Injection Industry Trends
  2. 9.2 Adalimumab Injection Industry Drivers
  3. 9.3 Adalimumab Injection Industry Opportunities and Challenges
  4. 9.4 Adalimumab Injection Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research, Inc.
      Talk to an analyst